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Long-term treatment with hydralazine is sometimes associated with deposition of immune complexes and 
development of systemic lupus erythematosus (SLE) as an adverse side-effect. Hydralazine inhibits the cova- 
lent binding reaction of the complement protein C4. We show that when hydralazine inhibits C4, it becomes 
covalently bound to the polypeptide chain containing the active site thiol ester. C4 is encoded at 2 adjacent 
polymorphic loci, C4A and C4B, within the major histocompatibility complex. We show that hydralazine 
binds more effkiently to the C4A than to the C4B gene product and suggest hat C4 type may predispose 
patients to hydralazine-induced SLE. 
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1. INTRODUCTION 
Some patients who are treated with hydralazine, 
an anti-hypertensive drug, develop symptoms 
resembling systemic lupus erythematosus [I] with 
deposition of immune complexes predominantly in 
the vascular epithelium but also in other tissues [2]. 
The complement system is closely involved in im- 
mune complex handling, stimulating phagocytosis 
[3] and solubilization [4] through covalent binding 
of C3. Solubilization of preformed immune com- 
plexes [5] and inhibition of precipitation of im- 
mune complexes [6] occur more effectively via the 
classical complement pathway. So inhibition of the 
early components, Cl, C2 or C4, would be likely 
to increase the size of immune complexes. Since in- 
dividuals who lack the early complement proteins 
are at increased risk of developing idiopathic SLE 
[7], it does seem as if the association between an in- 
hibited complement pathway and immune complex 
deposition is important in the pathology of SLE. 
When the classical pathway is activated by im- 
mune complexes, C4 is cleaved by the protease 
Cls. Activated C4 binds covalently to the immune 
complex [S] (or other activating surface) as C4b 
which then serves as part of the complex enzyme 
which activates C3 and causes it to bind covalently 
as C3b by the same mechanism [9,10]. It has been 
suggested that hydralazine induces SLE in suscep- 
tible individuals by inhibiting the covalent binding 
reaction of C4 [ 111. Hydralazine is a substituted 
hydrazine (fig.l), and it has been shown that when 
another substituted hydrazine, phenylhydrazine, 
inhibits covalent binding of activated C3, the com- 
pound becomes covalently bound to the protein 
[ 121. To substantiate the proposed molecular basis 
of hydralazine inhibition of C4, we therefore in- 
vestigated whether hydralazine becomes covalently 
bound to activated C4. 
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Fig. 1. Hydralazine. 
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With doses of hydralazine of less than 
200 mg/day the proportion of patients who 
develop adverse effects may be less than 5% [13] 
although 11% of female patients have been 
reported to show the lupus syndrome [14]. These 
incidence figures suggest hat the genetic make-up 
of those who develop hydralazine lupus is impor- 
tant. Hydralazine is metabolised by a polymorphic 
N-acetyltransferase and acetylator phenotype [ 131 
is partly responsible since the syndrome develops 
almost exclusively in patients of the slow acetylator 
phenotype. Women are also at increased risk 
[ 13,141. C4 is a class III MHC antigen and both the 
C4A and the C4B loci are highly polymorphic [ 151. 
C4A corresponds to the Rodgers blood group an- 
tigen and C4B to Chido [ 161. It has previously been 
demonstrated that C4A is more reactive with 
amino nucleophiles than C4B [17,18]. To test 
whether C4 polymorphism could provide another 
factor in determining predisposition to hydra- 
lazine-induced lupus, we have looked at C4A and 
C4B to determine if they differ in susceptibility to 
inhibition by hydralazine. 
2. MATERIALS AND METHODS 
2.1. Proteins 
CG was prepared from human serum and C4 
from pooled human plasma as described [1 I]. C4A 
was prepared from Rodgers positive/Chid0 
negative plasma and C4B from Chido positive/ 
Rodgers negative plasma as described [ 181. Chido 
or Rodgers typed plasmas were confirmed to be 
C4Bl or C4A3, respectively, by MS A. Fielder, 
Department of Immunology, Royal Post Graduate 
Medical School, London. 
2.2. Binding of hydralazine to C4b 
To demonstrate the covalent binding of 
hydralazine to C4b, C4 (168 pg) was incubated 
(20 min, 37°C) with or without Cc (6 pg) in a 
total volume of 250~1 of 10 mM sodium 
phosphate, 145 mM NaCl, pH 7.5 (PBS), contain- 
ing up to 5 mM [14C]hydralazine (spec. act. 
19.8 mCi/mmol; Amersham International, Eng- 
land). Protein was precipitated at 4°C (16 h) with 
10% (w/v) trichloroacetic acid. Pellets were 
washed twice with 1 ml of ice-cold trichloroacetic 
acid (lo%, w/v) containing 10 mM hydralazine, 
then twice with 1 ml of ice-cold acetone. Pellets 
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were resuspended in 80 ~1 of 100 mM Tris-HCl, 
pH 6.8, 4 M urea, 1% (w/v) SDS containing 
3 mg/ml of dithiothreitol. After reduction and 
alkylation, samples were electrophoresed on 7.5% 
polyacrylamide gels containing SDS. Gels were 
stained for protein as before [ 111. The positions of 
radioactive bands were determined by fluorog- 
raphy [19] using Fuji RX X-ray film. Alterna- 
tively, the C4 (Y and LY’ region was cut out of the 
gel, solubilised with NCS tissue solubiliser and 
radioactivity was determined in an LKB-Wallac 
Ultrabeta scintillation counter. 
2.3. Binding of C4 to Sepharose-Cls 
Pooled C4, C4A and C4B were also labelled 
with “‘1 using Iodobeads (Pierce) and inhibition 
of binding of 1251-C4 to Sepharose-CG was 
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Fig.2. Binding of [14C]hydralazine to C4 on activation 
by CG. Track 1, “‘I-C4 + PBS (control); track 2Lz51- 
C4 + Cls (control); track 3, C4 + Cls + 
[r4C]hydralazine (5 mM); track 4, C4 + PBS + 
[4C]hydralazine (5 mM). Incubations were performed as 
described in section 2 except that for control samples 
20000 cpm of 1251-labelled C4 was added. 
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measured as described [111. The rate of cleavage of 
“‘1-C4A and “‘1-C4B by Cz was the same as 
determined by the rate of appearance of the LY’ 
chain on S~S-polyacrylamide gel electrophoresis. 
The positions of iodinated protein bands were 
determined by autoradiography as in [ 111. 
3. RESULTS 
When C4 prepared from pooled human plasma 
is activated by CG in the presence of 
[14C]hydralazine, the drug becomes covalently 
bound to the LY’ chain of C4b (fig.2, track 3). With 
no Cls present (fig.2, track 4), [‘4C]hydralazine is 
not incorporated. If preformed C4b is incubated 
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Fig.3. Time course of covalent binding of rz51-C4A and 
**‘I-C4B to Sepharose-Cls. Incubation mixtures 
contained Id cpm of ‘*‘I-C4A or ‘*‘I-C4B in 200 pl of 
25% (v/v) Sepharose-Cls in PBS. After various times at 
37*C, the reaction was stopped and radioactivity 
associated with the pellet was measured as before ill]. 
Non-covalently bound radioactivity associated with the 
pellet, which was less than 1070 of the radioactivity 
supplied, was measured in the presence of 20 mM 
NHzOH Ill]. (0) C4A, (0) C4B. 
with [‘4C]hydralazine, then no radioactivity is 
bound (not shown). 
The binding of i2’I-C4A and “‘I-C4B to 
Sepharose-C% has been measured as a function of 
time (fig.3). The i2?-C4B protein binds more 
rapidly and to a greater extent than 12?-C4A. 
The binding of hydralazine to C4A and C4B has 
been measured and it is clear that more hydralazine 
binds to C4A than to C4B (table 1). 
The inhibition of binding of “251-C4A or 12?- 
C4B to Sepharose-CG by hydralazine shows that 
the C4A type is more readily inhibited by 
hydralazine than C4B (fig.4). 50% inhibition of 
C4A binding occurs at 550pM whereas 50% of 
C4B binding is inhibited at 2 mM hydr~azine. 
These results are in good agreement with the value 
of 50% inhibition of C4 from pooled human 
plasma which is 840 FM [ 111. 
Fig.4. Hydralazine inhibit& of binding of t2%C4A and 
“‘I-C4B to Sepharose-Cls. ‘*%C4A (e) or it51-C4B 
(0) (lo6 cpm) was incubated with Sepharose-Cls (25Or0, 
v/v) for 30 min at 37°C with or without hydralazine in 
a total volume of 200~1 PBS. The radioactivity 
associated with the pellets and the percentage inhibition 
was determined as described before [II]. 
Table I 
Binding of [14C]hydralazine to C4A and C4B 
[‘4C)Hydraiazine 
(mM) 
cpm in CY/E’ region of 
SDS-polyacrylamide gel 
C4A C4B 
0.07 139 33 
0.60 448 270 
2.13 1780 962 
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4. DISCUSSION ACKNOWLEDGEMENTS 
C4, like C3, contains an intrachain thiol ester 
bond which on proteol~ic activation becomes ex- 
posed and available for reaction for a very short 
time (probably less than 1 ms) [12] with 
nucleophilic compounds, including putrescine [20] 
and phenylhydrazine [ 121. Putrescine has been 
shown to become bound to C4 by a tram-acylation 
reaction to glutamate in the thiol ester site. 
[14C]Hydralazine, which is also nucleophilic 
(fig.l), is found covalently bound to the LY’ 
polypeptide chain of C4b only when the drug is 
present during activation of C4 by C6. Since the 
thiol ester site is in the cy’ chain, it is likely that 
hydralazine also binds to this group in C4. These 
results provide a chemical basis for the earlier 
observation that hydralazine will inhibit the 
covalent binding of C4 to an activating surface 
[ 1 I]. A possible outcome of the binding of 
hydralazine to activated C4 is that the drug may 
then act as a hapten and there have been reports of 
antihydraiazine antibodies in adverse reactions to 
hydralazine [21,22]. 
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